MarketCap
Facebook
X
TelegramQuarterly report 2024-Q3
added 10-28-2024
Inari Medical Accounts Receivables 2011-2026 | NARI
Accounts receivable — is the amount of money owed to a company by other organizations, individuals, or the government. It arises when a company has already delivered goods, performed work, or provided services, but has not yet received payment for them.Examples of accounts receivable
- Customers have not paid invoices for delivered products
- An advance has been paid to a supplier, but goods have not yet been received
- Employees have not reported on accountable amounts
- The government must refund tax overpayments
- Outstanding loans issued
- Asset quality
Accounts receivable are part of current assets. But they are not cash — they are promises. Investors assess how realistic these promises are to be collected. The higher the share of overdue or doubtful receivables, the greater the risk of asset impairment. - Impact on cash flow
Even if a company shows a profit, the money can be "tied up" in receivables. This means profit does not turn into actual cash, and the company may face liquidity shortages. - Assessment of management efficiency
The following accounts receivable turnover ratios are commonly used:
Receivables turnover = Revenue / Average accounts receivable
(the higher — the better)
Days Sales Outstanding (DSO) = 365 / Turnover
(the fewer days — the faster customers pay)
If the DSO is constantly increasing — this is a red flag — customers are delaying payments, and money gets stuck in settlements.
Annual Accounts Receivables Inari Medical
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 58.6 M | 42.4 M | 28 M | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 58.6 M | 28 M | 43 M |
Quarterly Accounts Receivables Inari Medical
| 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 84.4 M | 81.6 M | 78.6 M | 70.1 M | 69.6 M | 63.1 M | 55.7 M | 58.6 M | 54.1 M | - | 45 M | 42.4 M | 38.9 M | 31.5 M | 31.3 M | 28 M | 28 M | 28 M | 28 M | 11.3 M | 11.3 M | 11.3 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 84.4 M | 11.3 M | 45.3 M |
Accounts Receivables of other stocks in the Medical devices industry
| Issuer | Accounts Receivables | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
EDAP TMS S.A.
EDAP
|
18.6 M | $ 3.28 | - | $ 123 M |  France |
 |
Electromed
ELMD
|
24.7 M | $ 25.74 | - | $ 218 M |  USA |
 |
Apollo Endosurgery
APEN
|
15 M | - | - | $ 475 M | USA |
 |
Globus Medical
GMED
|
679 M | $ 90.74 | - | $ 12.3 B | USA |
 |
Helius Medical Technologies
HSDT
|
117 K | $ 2.08 | - | $ 1.26 M | USA |
 |
Aziyo Biologics
AZYO
|
1.73 M | - | 1.37 % | $ 20.5 M | USA |
 |
AdaptHealth Corp.
AHCO
|
371 M | $ 13.38 | - | $ 1.81 B | USA |
 |
Allied Healthcare Products
AHPI
|
2.37 M | - | 3.58 % | $ 2.21 M | USA |
 |
Avinger
AVGR
|
1.01 M | - | -20.74 % | $ 369 K | USA |
 |
BIOLASE
BIOL
|
5.48 M | - | -13.19 % | $ 166 K | USA |
 |
Axonics Modulation Technologies
AXNX
|
44.8 M | - | - | $ 3.31 B | USA |
 |
Pulmonx Corporation
LUNG
|
12.1 M | $ 1.23 | - | $ 50 M | USA |
 |
BioSig Technologies
BSGM
|
109 K | - | 37.08 % | $ 85.7 M | USA |
 |
Orthofix Medical
OFIX
|
136 M | $ 11.91 | - | $ 472 M |  Curacao |
 |
Conformis
CFMS
|
9.77 M | - | - | $ 16.4 M | USA |
 |
Insulet Corporation
PODD
|
161 M | $ 182.87 | - | $ 12.9 B | USA |
 |
Cardiovascular Systems
CSII
|
39.7 M | - | 0.15 % | $ 844 M | USA |
 |
Cytosorbents Corporation
CTSO
|
7.55 M | $ 0.6 | -1.96 % | $ 37.3 M | USA |
 |
Sintx Technologies
SINT
|
178 K | $ 2.15 | - | $ 5.96 M | USA |
 |
ClearPoint Neuro
CLPT
|
6.55 M | $ 11.08 | - | $ 314 M | USA |
 |
Dynatronics Corporation
DYNT
|
2.8 M | - | 14.99 % | $ 929 K | USA |
 |
Eargo
EAR
|
1.91 M | - | - | $ 10.2 M | USA |
 |
Stryker Corporation
SYK
|
4.04 B | $ 321.43 | -0.02 % | $ 123 B | USA |
 |
Tactile Systems Technology
TCMD
|
43.9 M | $ 23.57 | - | $ 539 M | USA |
 |
TELA Bio
TELA
|
10.3 M | $ 0.78 | - | $ 36.6 M | USA |
 |
Second Sight Medical Products
EYES
|
455 K | - | -0.97 % | $ 54.4 M | USA |
 |
TransMedics Group
TMDX
|
84.3 M | $ 101.26 | - | $ 3.44 B | USA |
 |
Tandem Diabetes Care
TNDM
|
165 M | $ 18.63 | - | $ 1.27 B | USA |
 |
GBS
GBS
|
595 K | - | -0.57 % | $ 7.12 M | USA |
 |
Varex Imaging Corporation
VREX
|
157 M | $ 12.07 | - | $ 500 M | USA |
 |
Butterfly Network
BFLY
|
20.8 M | $ 5.16 | - | $ 1.09 B | USA |
 |
Vivos Therapeutics
VVOS
|
1.58 M | $ 0.85 | - | $ 8.73 M | USA |
 |
Beyond Air
XAIR
|
710 K | $ 0.51 | - | $ 34.5 M | USA |
 |
OrthoPediatrics Corp.
KIDS
|
53.8 M | $ 15.14 | - | $ 355 M | USA |
 |
Delcath Systems
DCTH
|
11.7 M | $ 10.55 | - | $ 378 M | USA |
 |
Xtant Medical Holdings
XTNT
|
17.8 M | $ 0.55 | -1.78 % | $ 76.7 M | USA |
 |
Zimmer Biomet Holdings
ZBH
|
1.48 B | $ 82.8 | - | $ 16.8 B | USA |
 |
IRIDEX Corporation
IRIX
|
7.61 M | $ 1.04 | - | $ 17.6 M | USA |
 |
CONMED Corporation
CNMD
|
248 M | $ 36.79 | - | $ 1.14 B | USA |